Free shipping on all orders over $ 500

Balixafortide

Cat. No. M27720
Balixafortide Structure
Synonym:

POL6326

Size Price Availability Quantity
5mg USD 170  USD170 In stock
10mg USD 300  USD300 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects.

Chemical Information
Molecular Weight 1864.14
Formula C84H118N24O21S2
CAS Number 1051366-32-5
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Tyler Robinson, et al. Prostate. A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis

[2] Gokhan Batur, et al. Chimia (Aarau). Macrocycle Therapeutics to Treat Life-threatening Diseases

[3] Miao Miao, et al. Expert Opin Drug Metab Toxicol. Clinical significance of chemokine receptor antagonists

[4] Sonia Pernas, et al. Lancet Oncol. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

[5] Darja Karpova, et al. J Transl Med. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial

Related CXCR Products
ML339

ML339 is a selective CXCR6 antagonist with an IC50 of 140 nM. ML339 has no inhibitory effect on CXCR5, CXCR4 and apelin receptor (APJ).

FC131 TFA

FC131 TFA is a CXCR4 antagonist, inhibits [125I]-SDF-1 binding to CXCR4, with an IC50 of 4.5 nM.

CTCE-0214

CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog.

TC14012

TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM.

CXCR4 antagonist 4

CXCR4 antagonist 4 is a potent, orally active CXCR4 antagonist (IC50=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC50=7 nM).

  Catalog
Abmole Inhibitor Catalog




Keywords: Balixafortide, POL6326 supplier, CXCR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.